If you’re one of the many people chowing down on melatonin gummies to help get to sleep, you may want to check out this study.

A new piece of research published by the American Heart Association made an alarming discovery about long-term use of melatonin supplements, an over-the-counter sleep aid used by tens of thousands. Basically, those who use melatonin over a year or more had a 90 percent higher risk of developing congestive heart failure over a five-year period.

Before you go flush your gummies down the toilet, there are a few caveats. For starters, the findings weren’t based on a clinical trial, but on data from a large database of anonymous health records. Researchers drew from data on chronic insomniacs, specifically, splitting them into two groups: those who have dosed the sleep-regulating hormone over a period of 12 months or more, and those who suffer without.

Still, the results are clearly worrisome. Overall, the study found that 4.6 percent of the melatonin group went on to develop heart failure, compared to 2.7 percent for the control group.

That wasn’t the only data point suggesting it may be time to wean off the ‘tone. A secondary analysis performed by the researchers found that melatonin users were nearly 3.5 times more likely to be hospitalized for heart failure than those in the other group, with hospitalization rates of 19.0 and 6.6 percent, respectively.

“Melatonin supplements are widely thought of as a safe and ‘natural’ option to support better sleep, so it was striking to see such consistent and significant increases in serious health outcomes, even after balancing for many other risk factors,” Ekenedilichukwu Nnadi, the study’s lead author and chief resident in internal medicine at SUNY Brooklyn, said in a press release.

While more in-depth research is needed to confirm the study’s results, the early findings indicate that melatonin use comes with some serious risks in the long-term.

“Melatonin supplements may not be as harmless as commonly assumed,” as Nnadi explained. “If our study is confirmed, this could affect how doctors counsel patients about sleep aids.”

More on health studies: The Hectic Modern World Is Shredding Your Little Cave Man Brain, Scientists Confirm

The post Melatonin Use Linked to Massively Increased Risk of Heart Failure appeared first on Futurism.

Prediction markets like Kalshi and Polymarket have long garnered a reputation for allowing users to make all kinds of ethically dubious bets, from the outcomes of deadly conflicts to mass famine. 

As the New York Times reports, Kalshi will now even allow users to bet on whether clinical trials for potentially lifesaving drugs will succeed.

To critics, the move will effectively allow betting on the lives of patients trying a final intervention in the face of a lethal diagnosis. There’s even risk that those enrolled in these trials could choose to drop out if the market were to bet against a positive outcome.

“Turning loose a betting market in an ongoing randomized clinical trial really is a breach of scientific conduct,” Robert Califf, who served as FDA commissioner in the Biden administration, told the NYT.

Kalshi first announced its “biotech prediction markets pilot program” last month, the same day president Donald Trump’s teleprompter guy was busted for winning more than $100,000 on Kalshi by betting on what he would say.

The company argued in the announcement that a “publicly listed contract on a trial or regulatory outcome produces a continuously updated, public probability that reflects the weight of the evidence rather than the preferred messaging of the trial sponsor.”

In a statement to the NYT, spokesperson Jack Such argued that these bets wouldn’t undermine research integrity, but instead cut through the hype surrounding biotech companies and the drugs they’re working on. 

Kalshi says it will prohibit betting by patients enrolled in a trial, as well as by employees of the company conducting it or its competitors, per the NYT. It will also ban betting on trials that “exclusively enroll minors,” at least at first.

But those enrolled in drug trials were left appalled by the news.

“We’re literally trying to stay alive,” metastatic pancreatic cancer patient Walter Ingaharro Jr told the NYT. “It’s not a game. The introduction of gambling into the process really creates an ethical mess.”

In an opinion piece for The Guardian, Boston University humanities professor Joshua Pederson talked about how his 12-year-old son has a “very aggressive tumor growing inches below his heart.”

“If Kalshi has its way, you could soon be able to bet on health treatments that could be essential to his survival,” Pederson argued.

While choosing a trial for his son’s cancer was a “terrifying experiment for which we feel ill-prepared,” turning to a prediction market instead of “our extremely qualified team of oncologists” feels “preposterous,” Pederson argued.

In short, it’s yet another example of prediction markets crossing a moral boundary by gamifying things with real-world consequences.

“The possibility that somebody out there might be wagering against my son, hoping that the treatment fails so they can make money, is enraging,” Pederson wrote. “How is this not just another type of ‘death market’ — like markets for war or assassination — that even Kalshi says it won’t abide?”

The headline of this story was updated to specify that the program would bet on the outcomes of clinical trials, and the piece was updated to more specifically refer to controversies around prediction markets like Kalshi, writ large, and to add details about Kalshi’s response.

More on prediction markets: In Case You Still Think Insider Trading on Prediction Markets Isn’t Real, Trump’s Teleprompter Guy Just Got Busted for Getting Rich on Betting What He Would Say

The post Kalshi Defends Plan to Bet on Outcomes of Clinical Trials appeared first on Futurism.

Psilocybin therapy involves more than the compound itself, and a new research initiative at the University of Southern California is investigating the effects of combining psilocybin with structured mental training.

A team from the Keck School of Medicine of USC, working with the USC Dornsife Brain and Creativity Institute and the USC Norris Comprehensive Cancer Center, has begun the university’s first clinical trial of psychedelic therapy. The study will examine whether structured mindfulness meditation can boost the effects of psilocybin, the active ingredient in psychedelic mushrooms, on mental well-being and cognitive performance.

Funding for the trial comes from ARPA-H’s EVIDENT initiative, a federal program designed to accelerate the development of rapid-acting treatments for mental and behavioral health conditions. The study will investigate whether adding mindfulness training to psilocybin-assisted therapy yields outcomes distinct from those of psilocybin-assisted therapy alone.

A Schedule 1 Drug With a Breakthrough Label

Although the Controlled Substances Act still classifies psilocybin as a Schedule I substance, the FDA has granted it a breakthrough therapy designation for major depressive disorder and treatment-resistant depression. In clinical settings, psilocybin has shown promise in treating these conditions, and other studies suggest it may also help with addiction.

Psilocybin alters a person’s perception, mood, and thought processes, and can influence how individuals experience their senses and their sense of time and space. With therapeutic support, people often report emotionally meaningful or spiritual experiences during these altered states.

Testing Whether Mental Training Changes the Outcome

About 72 middle-aged adults from the Los Angeles area will take part in the study. All participants will have no psychiatric or medical conditions and no previous experience with either psychedelics or meditation. Researchers will assign participants to one of two groups: one will receive supervised psilocybin alone, while the other will receive psilocybin alongside an eight-week mindfulness training program designed to build attention and focus through structured meditation.

The study is based on the hypothesis that mindfulness training, which has demonstrated mental and physical health benefits independently, may enhance the effects of psilocybin-assisted therapy when used together.

“Mindfulness meditation practice provides people with the tools to deconstruct unhelpful narratives, a process that may be amplified by psilocybin-assisted therapy,” said Rael Cahn, MD, PhD, director of the USC Center for Mindfulness Science and the study’s co-lead. The trial, he said, is meant to clarify how combining the two approaches “may enhance both the potential immediate and longer-term effects of psychedelic medicine.”

An Unusually Deep Data Set

The team will collect extensive biological, neurological, and psychological data from participants throughout the study. Participants will undergo EEG scans, brain MRI and fMRI imaging, and provide saliva, blood, and stool samples. Researchers will administer psychological and cognitive assessments before and after treatment and will survey participants again at three, six, and twelve months.

The team will use the data to track changes across psychological, cognitive, neurological, and biological measures, including well-being, spirituality, brain activity, and markers of inflammation and brain health. The open-label design means both participants and researchers are aware of group assignments, which allows for more comprehensive data collection at the expense of some blinding rigor.

Through the EVIDENT initiative, researchers will contribute anonymized trial results to a national repository. The resource will help researchers identify broader patterns in rapid-acting mental health treatments.

“Psilocybin-assisted therapy has the potential to revolutionize how we approach mental health research,” said Caryn Lerman, PhD, director of the USC Norris Comprehensive Cancer Center and the study’s other co-lead. Beyond addiction, she said, there’s growing evidence the treatment could improve “quality of life and emotional well-being for people facing serious illness and end-of-life challenges.”

A Test Case for the Next Wave of Psychedelic Medicine

If mindfulness training is shown to enhance the effects of psilocybin therapy, future protocols for psychedelic treatment may incorporate mental training as an additional component of treatment. Regardless of the outcome, the study will generate one of the most detailed biological and psychological datasets from a psilocybin trial to date.

Whether mindfulness ultimately amplifies psilocybin’s effects remains an open question. By tracking participants’ brains, biology, and psychological well-being over the course of a year, the USC team hopes to generate some of the clearest data yet on how mindset and psychedelic medicine interact.

Austin Burgess is a writer and researcher with a background in sales, marketing, and data analytics. He holds an MBA, a Bachelor of Science in Business Administration, and a data analytics certification. His work focuses on breaking scientific developments, with an emphasis on emerging biology, cognitive neuroscience, and archaeological discoveries.

In a groundbreaking advancement in the treatment of metastatic urothelial cancer, a recent clinical trial has explored the synergistic potential of combining immune checkpoint inhibitors tremelimumab and durvalumab with the chemotherapeutic agent paclitaxel. This phase I/II ICRA trial, published in the prestigious Nature Communications, offers compelling evidence that dual immune modulation with or without chemotherapy may redefine therapeutic paradigms for this challenging malignancy. The innovative study meticulously investigates the safety profile, optimal dosing, and preliminary efficacy signals of these agents when administered simultaneously, charting a promising new course in oncologic therapeutics.

Urothelial carcinoma, predominantly affecting the bladder, represents a formidable oncological challenge due to its aggressive nature and propensity for metastasis upon progression. While immune checkpoint inhibitors have revolutionized cancer care by unleashing the host’s immune system against tumor cells, their efficacy as monotherapy in advanced urothelial cancer remains variable. Tremelimumab, a monoclonal antibody targeting CTLA-4, and durvalumab, an anti-PD-L1 antibody, function by disrupting distinct immunosuppressive pathways that tumors exploit to evade immune detection. The rationale behind combining these agents with paclitaxel—a cytotoxic drug known for interfering with microtubule dynamics—lies in the complementary mechanisms that might potentiate antitumor responses.

The trial enrolled patients with histologically confirmed metastatic urothelial cancer who had exhausted or were ineligible for standard therapeutic options. Participants received varying regimens comprising tremelimumab alone, tremelimumab plus durvalumab, and either combination with paclitaxel. This design sought to delineate the safety thresholds and dose-limiting toxicities while enabling exploratory analyses of clinical outcomes such as progression-free survival and objective response rates. Detailed immune profiling and biomarker assessments accompanied the clinical evaluations to decipher correlates of response and resistance.

Initial data reveal that the combination treatments are generally well tolerated, with adverse events consistent with known profiles of checkpoint inhibitors and chemotherapy. Immune-related adverse events—such as dermatitis, colitis, and endocrinopathies—were manageable within established guidelines, emphasizing the importance of vigilant monitoring and timely intervention. Importantly, no unexpected synergistic toxicities emerged, suggesting that these agents can be safely coadministered without exacerbating systemic toxicity.

From an efficacy standpoint, tremelimumab combined with durvalumab and paclitaxel demonstrated encouraging antitumor activity, surpassing response rates historically observed with any single agent in this patient cohort. Objective responses included significant tumor burden reductions, with some patients experiencing durable disease stabilization or partial remission. Notably, the addition of paclitaxel appeared to enhance immunogenic cell death, potentially promoting antigen presentation and T-cell activation, thus amplifying the therapeutic window of the checkpoint blockade.

Correlative translational studies provided insights into the immunological milieu shaping treatment responses. Tumor biopsies and peripheral blood analyses highlighted increased infiltration of CD8+ cytotoxic T lymphocytes and a concomitant decrease in immunosuppressive regulatory T cells in responders. Furthermore, upregulation of interferon-gamma signaling pathways and enhanced expression of antigen processing machinery were observed, aligning with the hypothesis that chemotherapy-induced immunogenicity synergizes with checkpoint inhibition to invigorate antitumor immunity.

Another pivotal observation was the heterogeneity in patient outcomes, underscoring the necessity for biomarker-driven patient stratification. Molecular profiling identified tumor mutational burden and PD-L1 expression levels as potential predictive biomarkers, although their roles require further validation. Intriguingly, emerging evidence suggests that tumor microenvironment features—such as cytokine profiles and myeloid cell populations—may also influence responsiveness, opening new avenues for personalized immunotherapy approaches.

The trial’s phased escalation design allowed for adaptive modifications based on interim results, optimizing dosing regimens to balance efficacy and safety. These methodological strengths enhance the reliability of conclusions drawn and set a precedent for future combination trials in urothelial carcinoma and beyond. Additionally, pharmacokinetic analyses confirmed that neither agent significantly altered the metabolism of the others, supporting their compatibility in combination therapies.

This landmark investigation contributes critical knowledge to the evolving landscape of bladder cancer treatment by demonstrating how rationally designed combinations of immune checkpoint inhibitors and chemotherapies can elicit potent antitumor effects in metastatic disease. Given the historically poor prognosis for advanced urothelial cancer, these findings herald a new era where multi-agent immunomodulation may offer renewed hope for patients. However, broader phase III studies will be essential to confirm survival benefits and thoroughly characterize long-term safety.

Moreover, the translational components embedded within this study exemplify the growing trend towards integrating laboratory science with clinical oncology. Such integrative approaches are crucial for unraveling the complex interplay between tumor biology and therapeutic interventions, ultimately facilitating the development of more effective, tailored treatments. The ICRA trial represents an exemplar of precision medicine in action, advancing beyond one-size-fits-all approaches towards nuanced, biomarker-informed strategies.

While the current research focuses on metastatic urothelial carcinoma, the implications extend to other malignancies where immune evasion is a critical obstacle. The dual blockade of CTLA-4 and PD-L1 pathways in concert with chemotherapeutic agents may prove universally applicable, prompting parallel investigations across diverse cancer types. Furthermore, understanding the mechanisms that underlie response and resistance could inform the design of next-generation immunotherapies, including combination regimens incorporating novel agents such as oncolytic viruses, vaccines, or cell-based therapies.

In the broader context of cancer immunotherapy, the trial reinforces the concept that combining immune checkpoint inhibitors with traditional cytotoxic chemotherapy can create a more hostile environment for cancer cells while simultaneously activating immune effector functions. This synergistic interaction leverages the strengths of both modalities: chemotherapy disrupts tumor cell replication and induces immunogenic cell death, while checkpoint inhibitors relieve inhibitory signals that dampen T-cell activity. Together, they orchestrate a multifaceted assault on cancer.

The success of this approach depends heavily on careful patient selection, vigilant management of immune-related adverse events, and comprehensive biomarker development. As immune therapies increasingly become standard in oncology, multidisciplinary collaborations between clinicians, immunologists, and computational biologists will be vital to fully harness their potential. The ICRA trial epitomizes such collaborative effort, merging clinical expertise with cutting-edge immunological research.

In summary, the phase I/II ICRA trial investigating tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer delineates a compelling therapeutic strategy blending checkpoint blockade and chemotherapy. It underscores important principles regarding safety, efficacy, and mechanistic synergy while illuminating paths for future exploration. As the oncology community eagerly awaits results from larger confirmatory studies, this trial stands as a milestone in the continuous quest to improve outcomes for patients facing this formidable disease.

---

Subject of Research: Combination immunotherapy with tremelimumab and durvalumab alongside paclitaxel chemotherapy in metastatic urothelial cancer.

Article Title: Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Article References: Einerhand, S.M.H., Ali, H., Wong, S.Q. et al. Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74570-3

Image Credits: AI Generated

A groundbreaking clinical trial is underway at Leicester, spearheaded by leading researchers aiming to revolutionize treatment options for patients afflicted with mesothelioma, a particularly rare yet aggressive form of cancer. This innovative research offers a glimmer of hope to those affected, potentially extending their survival and enhancing quality of life by tailoring therapies to individual genetic profiles.

Mesothelioma arises predominantly in the linings of the lungs or abdomen and is intimately connected to asbestos exposure, a factor that has rendered this malignancy notoriously difficult to treat. Despite approximately 2,700 new diagnoses annually in the UK, prognosis remains grim, with survival rates and available treatment strategies offering limited success. Traditional therapies fail to adequately address the biological heterogeneity of this cancer, underscoring the urgent need for novel, personalized interventions.

Central to this trial, known as SELECTmeso1, is the use of targeted cancer therapies designed to exploit specific genetic vulnerabilities within tumor cells. This approach addresses the problem of variable treatment efficacy by stratifying patients based on identifiable genetic biomarkers, thus aligning therapeutic strategies with the molecular underpinnings of each patient’s disease. Trials like SELECTmeso1 embody the forefront of precision oncology, promising more effective and less toxic interventions.

The project is a collaboration between esteemed institutions including the NIHR Biomedical Research Centres in Leicester and Southampton, with the Southampton Clinical Trials Unit managing operations and oversight. Backed financially by Asthma + Lung UK, this research initiative emphasizes the growing recognition within the medical community of the importance of precision medicine in oncology, especially for diseases with limited therapeutic options like mesothelioma.

Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and lead investigator, highlights the crux of the personalized treatment paradigm: understanding the cancer’s unique genetic landscape. Nearly 50% of mesothelioma patients exhibit a deletion of the MTAP gene, a genetic anomaly that is intricately linked with more aggressive tumor behavior and resistance to conventional therapies. This genetic deletion simultaneously presents a distinctive therapeutic target.

The trial focuses on exploiting the absence of the MTAP gene to disrupt the cancer cells’ growth machinery selectively. In healthy cells, the MTAP gene is involved in critical metabolic pathways, but its deletion in cancer cells creates a biochemical dependency that can be targeted pharmacologically. The investigational drug, Navlimetostat (also referenced as BMS-986504), developed by pharmaceutical giant Bristol Myers Squibb, is a first-in-class PRMT5 inhibitor designed to exploit this metabolic vulnerability, thereby selectively inducing cancer cell death while sparing healthy tissue.

Navlimetostat operates by inhibiting protein arginine methyltransferase 5 (PRMT5), an enzyme crucial to the survival of cancer cells deficient in MTAP. By blocking PRMT5, Navlimetostat disrupts methylation-dependent processes vital to tumor cell proliferation and survival, effectively ‘starving’ the cancer at a molecular level. Early phase studies in other malignancies have shown promising anti-tumor activity and manageable safety profiles, laying a robust foundation for its evaluation in mesothelioma.

The SELECTmeso1 phase of the trial recruits patients with relapsed mesothelioma who test positive for the MTAP gene deletion. The trial administers Navlimetostat orally in three-week cycles, continuing up to six months. Researchers monitor both tumor response and patient tolerance meticulously, aiming to affirm the drug’s efficacy and safety within this highly specific patient subgroup.

This trial represents the initial stage of a larger adaptive platform study intending to evaluate multiple targeted agents against various genetic biomarkers across the spectrum of mesothelioma cases. By adopting a platform model, SELECTmeso aims to streamline clinical investigation, allowing simultaneous testing of several therapeutic candidates tailored to genetic signatures in patients’ tumors, thereby accelerating the pace of discovery and clinical translation.

Looking to the future, the platform design will incorporate molecular profiling of tumor samples to guide patient enrollment across sub-trials, each exploring a drug matched to a distinct biomarker. Such precision trials could transform the clinical landscape, enabling oncologists to offer bespoke therapies with improved outcomes versus the current ‘one-size-fits-all’ approach. Through this strategy, SELECTmeso1 pioneers a new chapter in mesothelioma treatment.

Dr. Samantha Walker of Asthma + Lung UK emphasizes the transformative potential of this research, especially given the dismal survival statistics and lack of curative options for mesothelioma patients. The advancement of targeted therapies has altered the natural history of multiple cancers, and the hope is that SELECTmeso1 will similarly deliver breakthroughs for this challenging disease, ultimately informing standard clinical practice worldwide.

The trial has already commenced recruitment at Leicester Royal Infirmary and will expand to ten additional UK hospitals, enrolling up to 30 patients for this initial evaluation. If successful, this could lay the groundwork for larger, practice-changing trials and establish a template for personalized cancer treatment paradigms not only for mesothelioma but also for other malignancies characterized by genetic heterogeneity.

In sum, the SELECTmeso1 trial exemplifies the cutting-edge intersection of genomics and oncology, demonstrating how understanding cancer’s molecular vulnerabilities can inform smarter, targeted treatments. It embodies the hope and progress achievable through collaborative research, innovative drug design, and precision medicine to improve survival and quality of life for patients facing devastating diagnoses.

---

Subject of Research: People

Article Title: Personalized Targeted Therapy Trial for Mesothelioma Opens New Frontiers in Cancer Treatment

News Publication Date: Not explicitly stated in source content

Web References:

• Leicester Biomedical Research Centre
• SCTU website
• Asthma + Lung UK
• MiST Trial Article
• CONFIRM Trial News
• NERO Trial News

References:
Cancer Research UK statistics on mesothelioma incidence and survival
Details of Navlimetostat (BMS-986504) as a first-in-class PRMT5 inhibitor by Bristol Myers Squibb

Image Credits: University of Leicester

Keywords: Mesothelioma, Targeted therapy, Personalized medicine, MTAP gene deletion, Navlimetostat, PRMT5 inhibitor, Clinical trial, Cancer research, Genetic biomarkers, Precision oncology, Cancer treatment, Drug development

In the ongoing battle against prostate cancer, one of the most formidable obstacles researchers and clinicians face is the cancer cells’ remarkable ability to develop resistance to treatments. These malignant cells employ sophisticated adaptive mechanisms to survive the onslaught of therapeutic agents, rendering many promising drugs less effective over time. A groundbreaking study led by Dr. Noel Warfel and his team at the MUSC Hollings Cancer Center has uncovered a hitherto unrecognized pathway that explains why certain protein-targeting drugs falter, offering fresh hope for more potent and durable therapies. Published in the latest issue of Cancer Letters, this research not only elucidates a novel survival mechanism in prostate cancer cells but also proposes an innovative therapeutic strategy to circumvent drug resistance.

At the heart of this discovery lies PIM1, a serine/threonine kinase well-known for its role in promoting prostate tumor growth, survival, and resistance to conventional therapies. Despite the development of various PIM1 inhibitors aimed at curbing its kinase activity, clinical success has been elusive, particularly in patients with solid tumors. The study probes the inadequacies of these conventional inhibitors and shifts the focus towards understanding the multifaceted biology of PIM1. Dr. Warfel’s work reveals that simply inhibiting PIM1’s enzymatic function does not fully neutralize its cancer-supporting properties, as the protein wields influence beyond its traditional kinase signaling.

Classically, kinase inhibitors designed to target PIM1 have been intended to block its enzymatic activity—effectively halting the phosphorylation events that drive tumor progression. However, Warfel’s team discovered that these drugs paradoxically cause an accumulation of PIM1 protein within cancer cells. Rather than being degraded, the surplus protein lingers and continues to facilitate cancer cell survival through kinase-independent mechanisms. This phenomenon results in a paradoxical biological double-edged sword: while inhibiting the enzyme’s catalytic function, the drugs inadvertently empower cancer cells with a fresh lifeline to resist death.

Key to this newly uncovered survival mechanism is the interaction between PIM1 and another protein known as HMGB1, a chromatin-binding factor usually confined to the nucleus. HMGB1 has a pivotal role in orchestrating cellular responses to DNA damage, but when PIM1 protein is abundant, these two form a complex that relocates HMGB1 from the nucleus to the cytoplasm. Once in the cytoplasm, HMGB1 ignites autophagy—a cellular recycling process that allows cancer cells to eliminate dysfunctional organelles, particularly damaged mitochondria.

Damaged mitochondria are notorious sources of reactive oxygen species and oxidative stress, conditions that can precipitate cell death. By facilitating the clearance of these harmful mitochondria, the PIM1-HMGB1 axis effectively lowers oxidative stress, bestowing cancer cells with a remarkable resilience against therapies designed to induce lethal damage. This mitophagy-driven defense mechanism enables prostate cancer cells to survive treatment regimens that would otherwise be effective, thus revealing a sophisticated layer of therapeutic evasion.

The implications of these findings are profound. They underscore a fundamental flaw in the current approach to drug design for kinase targets: the assumption that merely inhibiting the catalytic activity of a protein suffices to halt its oncogenic functions. Dr. Warfel emphasizes that the presence of the PIM1 protein itself—irrespective of its enzymatic activity—can sustain drug resistance, signaling a need for therapies that eliminate the protein entirely rather than merely neutralizing its kinase function.

In response to this challenge, the research team previously engineered a novel class of molecules known as proteolysis-targeting chimeras (PROTACs), specifically designed to induce the degradation of the PIM1 protein. Their lead compound, PIMTAC, capitalizes on the cell’s own proteasomal machinery to selectively tag and destroy PIM proteins, rather than simply inhibiting their kinase activity. Laboratory experiments and mouse model studies demonstrate that PIMTAC significantly enhances cancer cell death by increasing oxidative stress and disrupting the HMGB1-mediated survival pathway, outperforming conventional PIM1 inhibitors.

PIMTAC’s capacity to degrade PIM1 addresses both the signaling-dependent and -independent functions of the protein, offering a more comprehensive treatment strategy. By eliminating the kinase-independent survival effects, this approach holds promise for overcoming the persistent issue of drug resistance that hampers the efficacy of current therapies. The data suggest that this novel method could extend beyond prostate cancer to other malignancies where PIM proteins contribute to disease progression, including breast, lung, and various hematologic cancers.

While the development of PIMTAC represents a significant advance, the research remains in its preclinical phase. Challenges such as optimizing systemic delivery of the relatively large PROTAC molecule and improving its tumor-targeting specificity need to be addressed before clinical trials can commence. However, the insights gleaned from these studies reaffirm the importance of in-depth biological exploration of cancer targets, even those that have been the focus of research for many years.

This work also reflects a broader paradigm shift in oncology drug development. Increasing recognition of non-catalytic roles played by kinases and other oncogenic proteins suggests a future where protein degradation technologies might supersede traditional enzyme inhibition. Dr. Warfel envisions a landscape in which cancer therapeutics not only disable protein functions but remove the underlying protein itself, thereby dismantling multiple cancer-supportive mechanisms simultaneously.

Ultimately, this study epitomizes the continuous innovation and relentless inquiry needed to outsmart cancer’s adaptability. By uncovering a concealed survival pathway and offering a way to dismantle it, researchers add a crucial weapon to the anticancer arsenal. For patients battling advanced prostate cancer, particularly those facing the frustrations of treatment resistance, such advances kindle hope for more effective, durable therapies that can translate to improved outcomes and prolonged survival.

The journey from laboratory breakthrough to clinical application involves numerous hurdles, but endeavors like Dr. Warfel’s offer a compelling blueprint for future cancer research. Exploring the nuanced biology of proteins like PIM1 not only deepens scientific understanding but also fuels the creation of revolutionary treatments with the potential to save lives. This study stands as a testament to the power of reexamining established targets with fresh eyes and cutting-edge techniques, underscoring the importance of basic and translational research in reshaping cancer therapy.

As the medical community continues to explore the complexities of tumor biology, the integration of protein-targeting strategies such as PROTACs will likely play an instrumental role in overcoming therapeutic resistance. The PIM1-HMGB1 interaction and its influence on mitophagy highlight how intricate and multifaceted cancer cell survival mechanisms can be. Future investigations will undoubtedly build upon this foundational work, expanding the horizon of possibilities for precise, effective, and personalized cancer treatment modalities.

---

Subject of Research: Cells

Article Title: Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress

News Publication Date: 27-May-2026

Web References:

• Cancer Letters Article: https://www.sciencedirect.com/science/article/pii/S0304383526003745
• Previous related work: https://www.mdpi.com/2073-4409/11/6/1006

References: DOI: 10.1016/j.canlet.2026.218611

Image Credits: Medical University of South Carolina, Photo by Clif Rhodes

Keywords: Kinase inhibitors, Prostate cancer, Autophagy

In a groundbreaking study poised to redefine cancer immunotherapy paradigms, researchers have unveiled a programmable RNA engineering platform that restores immune recognition in notoriously immune-resistant tumors such as prostate cancer. This innovative approach, centered on precise manipulation of mRNA alternative polyadenylation (APA), revives the expression of major histocompatibility complex class I (MHC-I) molecules — the pivotal sentinels of immune surveillance routinely downregulated in these tumors. The findings, detailed in Nature Biomedical Engineering, shed light on an elusive molecular mechanism of immune evasion and herald a new frontier in translational cancer immunology.

Prostate cancer and analogous immune-cold tumors have long bedeviled clinicians by resisting immune checkpoint inhibitor therapies, a frontline strategy in modern oncology. A primary culprit in this resistance is the diminished presentation of tumor-specific antigens on MHC-I molecules, molecules intrinsically responsible for flagging abnormal cells to cytotoxic CD8 T cells. Without adequate MHC-I display, these malignant cells evade immune detection, rendering checkpoint blockade largely ineffective. Despite the clinical significance, no therapies have yet emerged that selectively restore MHC-I expression, underscoring a critical unmet medical need.

The investigative team addressed this gap by engineering the 3′UTR CRISPR/dCas13 system (3′UTRCES), an advanced RNA-editing platform designed to modulate mRNA 3′ untranslated region (3′UTR) dynamics in vivo. Unlike conventional gene editing tools that alter DNA sequences, 3′UTRCES uniquely targets RNA transcripts’ polyadenylation sites to manipulate APA patterns — a post-transcriptional regulatory mechanism influencing mRNA stability, localization, and translation. Leveraging a catalytically inactive Cas13 (dCas13) fused to programmable effectors, this system reprograms 3′UTR architecture to reinstate normal gene expression profiles critical for immune function.

Central to their discovery is the identification of tumor-specific 3′UTR shortening in the E3 ubiquitin ligase adaptor SPSB1, a molecular player hitherto not linked to immune modulation. Through sophisticated analyses, the researchers demonstrated that aberrant SPSB1 3′UTR truncations promote enhanced ubiquitination and subsequent degradation of MHC-I molecules. This selective downregulation disrupts the immune system’s ability to recognize and eliminate malignant cells without affecting programmed death-ligand 1 (PD-L1), an immune checkpoint protein. These insights decode a novel mechanism by which tumors suppress antigen presentation, bypassing immune control.

Armed with this mechanistic understanding, the team deployed lipid nanoparticle (LNP) delivery of the 3′UTRCES constructs directly into syngeneic mouse models harboring prostate tumors. This therapeutic intervention reversed the aberrant SPSB1 3′UTR shortening, effectively restoring MHC-I expression on tumor cells. The restored antigen presentation reinvigorated the infiltration of CD8 cytotoxic T lymphocytes, amplifying antitumor immune responses and sensitizing tumors to subsequent immune checkpoint therapies. This combinatorial strategy outperformed existing modalities, offering a tangible path to overcome immune resistance.

The implications of this study extend beyond prostate cancer, representing a conceptual shift in targeting post-transcriptional gene regulation to modulate tumor immunity. By precisely tailoring RNA isoforms through 3′UTRCES, it becomes feasible to rectify pathological gene expression patterns without permanent genomic alterations, minimizing off-target effects and paving the way for tunable, reversible therapies. This technological stride potentially positions LNP-3′UTRCES as a versatile platform for broad-spectrum cancer immunotherapy.

Delving deeper into the molecular underpinnings, the research highlights how alternative polyadenylation — once considered a subtle nuance of gene regulation — plays an outsized role in immune evasion. APA events that truncate key regulatory 3′UTRs can rewire protein expression profiles, impacting ubiquitin-mediated degradation pathways. In SPSB1’s case, 3′UTR shortening shields MHC-I from stable expression, underscoring the delicate interplay between RNA processing and immune visibility. These revelations chart a new investigative avenue for uncovering APA-driven oncogenic mechanisms.

The study harnessed state-of-the-art transcriptomic and proteomic methodologies to validate the APA signatures and subsequent functional outcomes. Single-cell RNA sequencing and cross-linking immunoprecipitation unveiled the precise RNA-protein interactions modulated by 3′UTR alterations. Meanwhile, in vivo tumor growth assays meticulously quantified the therapeutic efficacy of 3′UTRCES-mediated intervention. The robust experimental design marries molecular biology with immuno-oncology, reinforcing the translational promise of RNA engineering.

Beyond prostate cancer, the researchers posit that similar APA-driven immune escape mechanisms may underpin resistance in other malignancies characterized as immune-cold or immunologically excluded. Tumor heterogeneity presents obstacles, yet the adaptability of the 3′UTRCES platform offers a pathway to customize RNA editing interventions tailored to tumor-specific APA landscapes. This precision medicine approach aligns with emerging oncology paradigms striving to unify genetic and epigenetic therapeutic targeting.

Crucially, this work confronts a longstanding conceptual bottleneck — the absence of clinically viable modalities to restore MHC-I expression selectively. Immune checkpoint inhibitors, though transformative, rely heavily on intact antigen presentation machinery to elicit durable responses. By restoring the tumor’s antigen-presenting capacity, 3′UTRCES synergizes with immune checkpoint blockade, reinvigorating exhausted cytotoxic T cells and promoting tumor clearance. This paradigm underscores the importance of targeting upstream immune suppression pathways in cancer.

The LNP delivery mechanism employed is equally noteworthy, showcasing advances in nanomedicine that enable precise nucleic acid transport to tumor sites. Lipid nanoparticles offer biocompatibility, customizable surface chemistry, and efficient endosomal escape — attributes critical for clinical translation. As the field gravitates toward RNA-based therapeutics post-COVID-19, leveraging these delivery systems in oncology sets a precedent for future innovations combining synthetic biology and immunotherapy.

Looking ahead, the scalability and safety of 3′UTRCES-mediated therapies warrant thorough exploration through preclinical and clinical studies. Immunogenicity of RNA-guided effectors, off-target RNA interactions, and durability of therapeutic responses remain important considerations. Nevertheless, the current findings provide a compelling proof of concept, invigorating translational research efforts to combat immune escape mechanisms effectively.

This pioneering research not only reframes our understanding of tumor immune evasion but also exemplifies how RNA technology can be harnessed to unlock therapeutic opportunities in recalcitrant cancers. By transforming APA from a molecular signature of immune suppression into a therapeutic target, the study opens vistas for next-generation cancer treatments that restore immune competence at the RNA level. This convergence of molecular biology, immunotherapy, and RNA engineering heralds a new dawn in oncology innovation.

In summary, the programmable editing of mRNA 3′UTRs via the 3′UTRCES platform revitalizes MHC-I expression in prostate tumors, counteracting immune suppression driven by SPSB1-mediated degradation pathways. This novel mechanistic insight, coupled with effective lipid nanoparticle delivery and demonstrated synergy with immune checkpoint inhibitors, marks a transformative advance in overcoming tumor immune resistance. The study exemplifies how precision RNA engineering can recalibrate tumor immunogenicity and redefine therapeutic potentials in cancer treatment.

As research continues to unravel the complexities of RNA-mediated regulation of immune visibility in cancer, the integration of programmable RNA tools like 3′UTRCES with established immunotherapies holds immense promise. These synergistic strategies may soon accelerate the development of personalized cancer therapies designed to circumvent immune escape and foster more durable clinical remissions. The future of oncology may indeed lie at the interface of RNA engineering and immunomodulation.

This landmark work not only elucidates a previously unrecognized molecular mechanism of immune evasion but also delivers a versatile, programmable therapeutic platform for precise post-transcriptional gene regulation in cancer. Its translational implications inspire optimism for expanding the repertoire of RNA-based interventions that can be tailored to diverse tumor contexts, ultimately enhancing patient outcomes and transforming cancer immunotherapy at its molecular roots.

---

Subject of Research: Programmable RNA engineering to restore MHC-I expression and overcome immune evasion in prostate cancer.

Article Title: Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Article References:
Huang, F., Yuan, F., Li, K. et al. Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01720-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01720-9

The breast cancer 'breakthrough' is a story of overtreatment, not a triumph of testing, says Dr Clare Craig. The truth is, the genetic test failed, but it's being rolled out anyway.

The post The Breast Cancer ‘Breakthrough’ is a Story of Overtreatment Not a Triumph of Testing appeared first on The Daily Sceptic.